Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration

Medical Decision Making

Volumn 35, Issue 5, 2015, Pages 660-670

  McEwan, Phil ^a,b   Gordon, Jason ^b,e   Evans, Marc ^c   Ward, Thomas ^b   Bennett, Hayley ^a   Bergenheim, Klas ^d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^c Abertawe Bro Morgannwg University Health Board   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

cost effectiveness analysis.; decision aids; internal medicine; provider decision making

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; METFORMIN;

BLOOD; COST BENEFIT ANALYSIS; DECISION MAKING; DIABETES MELLITUS, TYPE 2; ECONOMIC MODEL; ECONOMICS; GREAT BRITAIN; HEALTH CARE COST; HUMAN; PRACTICE GUIDELINE;

COST-BENEFIT ANALYSIS; DECISION MAKING; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; GUIDELINES AS TOPIC; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; METFORMIN; MODELS, ECONOMIC;

EID: 84929960035     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X14565821     Document Type: Article

References (40)

1. Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011 ; 364 (9). 829-41
2. Sarwar N, Gao P, Seshasai SRK, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 ; 375 (9733). 2215-22
3. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetes Med. 2012 ; 29 (7). 855-62
4. Currie CJ, Gale EAM, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabetes Med. 2010 ; 27 (8). 938-48
5. Morgan CL, Peters JR, Dixon S, Currie CJ. Estimated costs of acute hospital care for people with diabetes in the United Kingdom: a routine record linkage study in a large region. Diabetes Med. 2010 ; 27 (9). 1066-73
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 ; 35 (6). 1364-79
7. Paschou SA, Leslie RD. Personalizing guidelines for diabetes management: twilight or dawn of the expert?. BMC Med. 2013 ; 11: 161
8. Type 2 diabetes. CG87. London, UK: National Institute for Health and Care Excellence ; 2014 :
9. Choudhary P, Amiel SA. Hypoglycaemia: current management and controversies. Postgrad Med J. 2011 ; 87 (1026). 298-306
10. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009 ; 11 (12). 1138-44
11. Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?. Diabetes Obes Metab. 2011 ; 13 (9). 823-31
12. Grandy S, Fox KM, Bazata DD. Health-related quality of life association with weight change in type 2 diabetes mellitus: perception vs. reality. Int J Clin Pract. 2013 ; 67 (5). 455-61
13. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005 ; 14 (3). 217-30
14. Palmer AJ. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting. Value Health. 2013 ; 16 (4). 670-685
15. McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006 ; 22 (1). 121-9
16. McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics. 2010 ; 28 (8). 665-74
17. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010 ; 12 (5). 431-6
18. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010 ; 12 (7). 623-30
19. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004 ; 47 (10). 1747-59
20. Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess. 2012 ; 16 (5). iii 1 - xiv 195
21. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Med. 2003 ; 20: 442-50
22. Clarke P, Gray A, Legood R, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002 ; 2 (4). 340-349
23. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health. 2005 ; 8: 581-90
24. Barry H, Ebell M, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Family Pract. 1997 ; 44 (1). 49-60
25. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014 ; 30 (7). 1267-73
26. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006 ; 22 (8). 15-23
27. Bennett H, McEwan P, Bergenheim K, Gordon J. Assessment of unmet clinical need in type 2 diabetic patients on conventional therapy in the UK.. :
28. Nauck MA, Del Prato S, Meier JJ, Durán-Garca S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 ; 34 (9). 2015-22
29. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 ; 20 (3). CD002966
30. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008 ; 81 (2). 184-9
31. British National Formulary. 65 th ed.London: BMJ Group and Pharmaceutical Press; 2013. London: BMJ Group and Pharmaceutical Press ; 2013 :
32. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013 ; 36 (11). 3411-7
33. Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. Diabetes Med. 2013 ; 30 (3). 300-8
34. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetes Med. 2010 ; 27 (3). 309-17
35. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011 ; 65 (5). 602-12
36. National Institute of Health and Care Excellence. Guide to the methods of technology appraisal. 2013. Available from: http://publications.nice.org.uk/pmg9
37. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012 ; 32 (5). 722-32
38. NICE technology appraisal guidance 288. Available from: www.guidance.nice.org.uk/ta288
39. McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011 ; 5 (1). e35 - e48
40. McIntosh B, Cameron C, Singh SR, Yu C, Dolovich L, Houlden R. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2012 ; 6 (2). e62-74